Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to ...

Company to Host Conference Call Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m.

YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of 2024, driven by sustained growth in prescriptions for ...

Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary ...

OptiNose (NASDAQ:OPTN – Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect OptiNose to post earnings of ($0.67 ...

EST OptiNose (OPTN) trading halted, volatility trading pauseDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists.

Members of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, March 20, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary ...